The ILLUMINATE Studies are phase 2 clinical research studies evaluating an investigational medication designed to reduce or eliminate the negative immune response to gluten in adults with celiac disease.
Continue ReadingAn analysis by an independent statistician of the ongoing Phase 3 trial for Larazotide has concluded that a substantial number of new patients would have to be added to the existing trial in order to get scientifically meaningful results.
Continue ReadingLast month, the Celiac Disease Foundation had the privilege of sponsoring the 2024 International Celiac Disease Symposium in Sheffield, UK. As the first patient advocate invited to chair and present on a scientific panel, CEO Marilyn Geller co-chaired the End Points in Clinical Trials session with Dr. Francisco Leon, CEO...